Hims & Hers Health Stock +9% Monday, Joining S&P 600 SmallCap
Hims & Hers Health Stock +9% Monday, Joining S&P 600 SmallCap
Hims & Hers Health shares also appear to be bouncing back after falling toward the end of last week after the U.S. Food and Drug Administration removed Eli Lilly's Mounjaro and Zepbound from the weight-loss and diabetes drugs shortage list.$Hims & Hers Health (HIMS.US)$ shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this week.
$Hims & Hers Health (HIMS.US)$ 股票周一交易走高。该公司本周将加入S&P SmallCap 600指数。
Hims & Hers Health shares are moving higher in anticipation of the company joining the S&P SmallCap 600 prior to the opening of trading on Wednesday. Hims & Hers Health shares jumped about 5% on the announcement late last week.
Hims & Hers Health股票价格上涨，预计该公司将于周三开盘前加入S&P SmallCap 600指数。Hims & Hers Health股票在上周末晚些时候的公告中上涨约5%。
Hims & Hers will replace Vector Group, which is being acquired by JT Group in a deal expected to close pending final conditions.
Hims & Hers将取代准备在最终条件满足后由Jt Group收购的Vector Group。
Hims & Hers Health shares also appear to be bouncing back after falling toward the end of last week after the U.S. Food and Drug Administration removed Eli Lilly's Mounjaro and Zepbound from the weight-loss and diabetes drugs shortage list.
Hims & Hers Health的股价在上周末降至最低后似乎出现反弹，此前美国食品和药物管理局将Eli Lilly的Mounjaro和Zepbound从减肥和糖尿病药物短缺名单中撤下。
The FDA said in a statement last week that Eli Lilly's supply can now keep up with current demand. Mounjaro had been on the regulator's shortage list since late 2022. Zepbound had been on the list since April. Hims & Hers Health shares fell on the news as the company sells cheaper versions, known as compounded drugs.
美国食品和药品管理局上周在一份声明中表示，Eli Lilly的供应现在可以满足目前的需求。Mounjaro自2022年底以来一直在监管机构的短缺名单上。Zepbound自4月以来一直在该名单上。Hims & Hers Health的股价因公司销售价格较便宜的版本，也就是复方药品而下跌。
